NCT00783211View on ClinicalTrials.gov

Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)

PHASE4CompletedINTERVENTIONAL
Enrollment

722

Participants

Timeline

Start Date

August 1, 2004

Primary Completion Date

October 1, 2004

Study Completion Date

October 1, 2004

Conditions
Seasonal Allergic Rhinitis
Interventions
DRUG

desloratadine

desloratadine, 5 mg oral tablets, once daily for 15 days

DRUG

fexofenadine

fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated

DRUG

placebo

placebo, once daily for 15 days

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00783211 - Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED) | Biotech Hunter | Biotech Hunter